WuXi Biologics Expands European Biologics Manufacturing Footprint
Event summary
- WuXi Biologics showcased its European biologics manufacturing capabilities at CPHI Milan 2026, highlighting its Dundalk (Ireland) and Wuppertal (Germany) sites.
- The company has passed 49 regulatory inspections, including 23 by the FDA and EMA, and secured 166 facility license approvals as of June 2026.
- WuXi Biologics operates a global manufacturing network with 54,000 L of drug-substance capacity in Dundalk and 12,000 L in Wuppertal, with expansion potential to 24,000 L.
- The company has supported 1,064 integrated projects, including 221 bispecific and multi-specific antibody projects and 328 ADC projects as of June 2026.
The big picture
The European biologics market is projected to grow at a CAGR of 8.1% from 2026 to 2035, driven by aging populations and the rising burden of chronic diseases. WuXi Biologics is positioning itself as a key player in this expanding market by leveraging its integrated CRDMO platform and strategically positioned operations in Europe. The company's focus on quality, supply resilience, and manufacturing excellence aligns with the industry's shift towards regional and resilient supply strategies.
What we're watching
- Regulatory Compliance
- Whether WuXi Biologics can maintain its strong regulatory track record amid increasing scrutiny and complex biologics pipelines.
- Supply Chain Resilience
- How the company's Global Dual Sourcing strategy will impact its ability to provide reliable supply in a fragmented biologics market.
- Technological Innovation
- The pace at which WuXi Biologics can integrate and scale its technology platforms, such as WuXia™ TrueSite and WuXiHigh™ 2.0, to support complex biologics development.
Related topics
